Nitroheterocyclic drugs with broad spectrum activity

Parasitology Research

Volumn 90, Issue SUPPL.1, 2003, Pages

  Raether, W ^a   Hanel H ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIPROTOZOAL AGENT; BENZNIDAZOLE; CIBA 32644; DIIODOHYDROXYQUIN; DILOXANIDE FUROATE; DIMETRIDAZOLE; FLUCYTOSINE; FURAZOLIDONE; HETEROCYCLIC COMPOUND; KETOCONAZOLE; METRONIDAZOLE; MICONAZOLE; MISONIDAZOLE; NIFURTIMOX; NIMORAZOLE; NIRIDAZOLE; NITAZOXANIDE; NITROFURAL; NITROIMIDAZOLE; ORNIDAZOLE; PAROMOMYCIN; SECNIDAZOLE; TINIDAZOLE;

AMEBIASIS; ANOREXIA; CARCINOGENICITY; CLINICAL FEATURE; CLINICAL TRIAL; CREAM; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG FECES LEVEL; DRUG FORMULATION; DRUG INDICATION; DRUG INDUCED CANCER; DRUG OXIDATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG URINE LEVEL; ENTAMOEBA HISTOLYTICA; FIRST PASS EFFECT; FLATULENCE; GENOTOXICITY; GIARDIASIS; HEADACHE; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INSOMNIA; MATERNAL DISEASE; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTOZOAL INFECTION; PSEUDOMEMBRANOUS COLITIS; RASH; REVIEW; SIDE EFFECT; STOMATITIS; STRUCTURE ACTIVITY RELATION; SUSPENSION; TERATOGENICITY; TINNITUS; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VERTIGO; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

ANIMALIA; BACTERIA (MICROORGANISMS); ENTAMOEBA; ENTAMOEBA HISTOLYTICA; PROTOZOA; TRICHOMONAS VAGINALIS;

EID: 0037963656     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-002-0754-9     Document Type: Review

References (51)

1. Adagu IS, Nolder D, Warhurst DC, Rossignol JF (2002) In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J Antimicrob Chemother 49:103-111
2. Andersson KE (1981) Pharmacokinetics of nitroimidazoles. Spectrum of adverse reactions. Scand J Infect Dis Suppl 26:60-67
3. Anonymous (1998) Drugs for parasitic infections. Med Lett 1017:1-12
4. Anonymous (2000) Drugs for parasitic infections. Med Lett 10801:1-12
5. Ash DV, Smith MR, Bugden RD (1979) Distribution of misonidazole in human tumors and normal tissues. Br J Cancer 39:503
6. Bergan T, Thorsteinsson SB (1986) Pharmacokinetics of metronidazole and its metabolites in reduced renal failure. Chemotherapy 32:305-318
7. Bergan T, Solhaug JH, Søreide O, Leinebø O (1985) Comparative clinical pharmacokinetics of metronidazole and tinidazole and their tissue penetration. Scand J Gastroenterol 20:945-950
8. Biagi GL (1982) The pharmacology and toxicology of 5-nitroimidazoles. In: Breccia A, Cavalleri B, Adams GE (eds) Nitroimidazoles (chemistry, pharmacology, and clinical application). Plenum Press, New York London, pp 1-7
9. Bhiraleus P, Roongpisuthipong A, Bhadrakom C, et al. (1990) Rapid eradication of trichomonads by single-dosed nimorazole. J Med Assoc Thai 73:119-123
10. Breccia A (1982) Chemical properties and reaction mechanism of nitroimidazoles. In: Breccia A, Cavalleri B, Adams GE (eds) Nitroimidazoles (chemistry, pharmacology, and clinical application). Plenum Press, London, pp 35-48
11. Brown DM, Upcroft JA, Dodd HN, Chen N, Upcroft P (1999) Alternative 2-keto acid oxidoreductase activities in Trichomonas vaginalis. Mol Biochem Parasitol 98:203-214
12. Cavalleri B (1982) Nitroimidazole chemistry I: synthetic methods. In: Breccia A, Cavalleri B, Adams GE (eds) Nitroimidazoles (chemistry, pharmacology, and clinical application). Plenum Press, New York, pp 9-33
13. Chambers HF (2001) Antimicrobial agents (general consideration). In: Goodman Gilman, A (consult ed), Hardman JG, Limbird LE (eds) The pharmacological basis of therapeutics, 10th int edn. McGraw-Hill, New York, pp 1143-1170
14. Cimerman B, Camilo Coura L, C Salle JM et al. (1997) Evaluation of Secnidazole gel and tinidazole suspension in the treatment of giardiasis in children. Braz J Infect Dis 1:241-247
15. Cottrill CP, Bishop K, Walton MI, Henk JM (1998) Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer. Int J Radiat Oncol Biol Phys 42:807-810
16. Freeman CD, Klutman NE, Lamp KC (1997) Metronidazole. A therapeutic review and update. Drugs 54:679-708
17. Gardner TB, Hill DR (2001) Treatment of giardiasis. Clin Microbiol Rev 14:114-128
18. Gilles HM, Hoffman PS (2002) Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol 18:95-97
19. Gillis JC, Wiseman LR (1996) Secnidazole, a review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in protozoan infections and bacterial vaginosis. Drugs 51:621-638
20. Haque R, Ali IK, Akther, S, Petri WAJr (1998) Comparision of PCR, isoenzyme analysis and antigen detection for diagnosis of Entamoeba histolytica infection J Clin Microbiol 36:449-452
21. Jessa MJ, Goddard AF, Barrett DA, Shaw PN, Spiller RC (1997) The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxy-metronidazole in human plasma, saliva and gastric juice. Br J Clin Pharmacol 44:245-253
22. John DT (1998) Opportunistic ameba. In: Cox FEG, Kreier JP, Wakelin D (eds) Topley and Wilsońs Microbiology and microbial infection, 9th edn, vol 5. Parasitology. ,Arnold, London, pp 179-192
23. Lamp KC, Freeman CD, Klutman NE, Lacy MK (1999) Pharmacokinetics and pharmacodynamics of nitroimidazole antimicrobials. Clin Pharmacokinet 36:353-373
24. Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danzinger LH (1992) Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet: 23:328-364
25. Mahfouz NM, Hassan MA (2001) Synthesis, chemical and enzymatic hydrolysis, and bioavailability evaluation in rabbits of metronidazole amino acid ester prodrugs with enhanced water solubility. J Pharmacol 53:841-848
26. Martin C, Bruguerolle B, Mallet MN et al. (1990) Pharmacokinetics and tissue penetration of a single dose of ornidazole (1 g intravenous) for antibiotic prophylaxis in colorectal surgery. Antimicrob Agents Chemother 34:1921-1924
27. Mehlhorn H (ed) (2001) Encyclopedic reference of parasitology, vol 1: biology-structure-function, vol 2. Diseases-treatment-therapy, 2nd edn. Springer, Berlin Heidelberg New York
28. Melgaard R, Kohler O, Hansen HS, Overgaard J et al. (1988) Misonidazole neuropathy. J Neurooncol 6:227-230
29. Minn H, Clavo AC, Fisher SJ, Wahl RL (2000) Effect of nitroimidazole sensitizers on in vitro glycolytic metabolism of hypoxic squamous cell carcinoma. Acta Oncol 39:199-205
30. Mitelman F, Strömbeck B, Ursing B, Nordle Ö, Hartley-Asp B (1982) Metronidazole exhibits no clastogenic activity in a double-blind cross-over study on Crohn' patients. Hereditas 96:279-286
31. Moselen JW, Hay MP, Denny WA, Wilson WR (1995) N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862) a bisnitroimidazole with enhanced selectivity as a bioreductive drug. Cancer Res 55:574-580
32. Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ, Gelone SP (1998) Difficult-to-treat trichomoniasis: result with paromomycin cream. Clin Infect Dis 26:986-988
33. Ortega YR, Adam RD (1997) Giardic overview and update. Clin Infect Dis 25:545-550
34. Pichard MM, Daujat M et al. (1992) Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary cultures. FASEB J 6:752-758
35. Pylkkänen L, Lähdetie J (1984) Sperm abnormality assay of metronidazole and tinidazole. Mutat Res 140:137-140
36. Qureshi H, Ali A, Baqai R, Ahmed W. (1997) Efficacy of a combined diloxanide furoate-metronidazole preparation in the treatment of ameobiasis and giardiasis. J Int Med Res 25:167-170
37. Raether W, Seidenath H (1983) The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica Ann Trop Med Parasitol 77:13-26
38. Raether W, Seidenath H, Winkelmann E (1977) 1,4-Bis-[1-methyl-5-nitroimidazolyl-(2-methylene-imino)]-piperazine, a new drug with marked activity against Entamoeba histolytica. Arzneimittelforschung (Drug Res) 27:968-969
39. Ravdin JI (2000) Amebiasis. Imperial College Press, London
40. Robson RA, Bailey RR, Sharman JR (1984) Tinidazole pharmacokinetics in severe renal failure. Clin Pharmacokinet 9:88-94
41. Roe FJC (1985) Safety of nitroimidazoles. Scand J Infect Dis Suppl 46:72-81
42. Schwartz DE, Hofheinz W (1982) Metabolism of nitroimidazoles. In: Breccia A, Cavalleri B, Adams GE (eds) Nitroimidazoles (chemistry, pharmacology, and clinical application). Plenum Press, New York London, pp 91-104
43. Stratford IJ, Adams GE (1982) Nitroimidazoles as hypoxia-mediated drugs in cancer chemotherapy. In: Breccia A, Cavalleri B, Adams GE (eds) Nitroimidazoles (chemistry, pharmacology, and clinical application). Plenum Press, New York, pp 67-81
44. Tracy JW, Webster TJr (2001) Drugs used in the chemotherapy of parasitc infections. In Godman, Gilman's(consult eds), Hardman JG, Limbird LE (eds) The pharmacological basis of therapeutics, 10th int edn. McGraw-Hill, New York, pp 1059-1140
45. Trussell RE (1947) Trichomonas vaginalis and trichomoniasis. Thomas, Springfield, Ill.
46. Williams KM (1984) Kinetics of misonidazole enantiomers. Clin Pharmacol Ther 36:817-823
47. Winkelmann E, Raether W (1978) Chemotherapeutically active nitro compounds 4. 5-Nitroimidazoles (Part III). Arzneimittelforschung (Drug Res) 28:739-749
48. Winkelmann E, Raether W, Gebert U (1978) Chemotherapeutically active nitro compounds 4. 5-Nitroimidazoles, part IV. Arzneimittelforschung (Drug Res) 28:1682-1684
49. Wood BA, Faulkner JK, Monro AM (1982) The pharmacokinetics, metabolism and tissue distribution of tinidazole. J Antimicrob Chemother 10 Suppl A:43-57
50. 14C tinidazole in humans. J Antimicrob Chemother 17:801-809
51. World Health Organisation (1989) Evaluation of certain veterinary drug residues in food. 34th report of the joint FAO/WHO expert committee on food additives. World Health Organ Tech Rep Ser 788